William Rayford Gwin III

Dr. William Rayford Gwin III is an Assistant Professor in the Division of Hematology and Oncology at the University of Washington School of Medicine and Assistant Professor in the Clinical Research Division at Fred Hutch Cancer Center. He serves as a Principal Investigator with UW Medicine's Cancer Vaccine Institute and is a board-certified medical oncologist specializing in breast cancer treatment.

Dr. Gwin completed his M.D. at the University of Alabama School of Medicine in 2006, followed by residency training at the University of Washington and fellowship in Oncology at Duke University Medical Center. He holds board certifications in Medical Oncology (2014), Hematology (2013), and Internal Medicine (2009) from the American Board of Internal Medicine.

His research focuses on the development of immune system-based therapies for breast and ovarian cancers, with particular emphasis on vaccines and checkpoint inhibitors. Dr. Gwin oversees clinical trials and manages patient care for those participating in immunotherapy studies. His work targets mechanisms of resistance to develop novel pre-clinical immunotherapies that transition into first-in-human clinical trials.

Analysis of his recent publications (2023-2025) reveals a strong focus on precision oncology approaches including biomarker-driven therapy selection, advanced imaging techniques (FES/FDG PET), and novel antibody-drug conjugates. His research spans from basic mechanisms of resistance to late recurrence prediction tools and clinical trial outcomes for HER2-positive breast cancer.

Dr. Gwin maintains active clinical practice at Fred Hutch Cancer Center's South Lake Union Clinic, where he provides personalized care for patients with all stages and types of breast cancer. He emphasizes understanding patients' lives and goals to support them throughout treatment.

He is affiliated with the Cancer Vaccine Institute at UW Medicine, where his laboratory work focuses on translating immunotherapeutic discoveries into clinical applications. His research team collaborates extensively with experts in immunology, molecular biology, and clinical oncology to advance cancer vaccine development.